NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

Core Insights - NuCana plc announced new data on NUC-3373, showing favorable efficacy and safety in heavily pre-treated patients with advanced solid tumors, particularly in combination with pembrolizumab [1][2] - The latest data indicates a patient with metastatic melanoma remains progression-free at 23 months, demonstrating a durable partial response [1][4] - Preclinical data supports the immunogenic effects of NUC-3373, enhancing immune cell activation and tumor cell death [2][4] Company Overview - NuCana is a clinical-stage biopharmaceutical company focused on improving cancer treatment outcomes through its ProTide technology, which transforms conventional chemotherapy agents into more effective and safer medicines [3] - The company's pipeline includes NUC-7738 and NUC-3373, with NUC-3373 being evaluated in a Phase 1b/2 modular study in combination with pembrolizumab for advanced solid tumors [5] Clinical Study Findings - In the NuTide:303 study, NUC-3373 combined with pembrolizumab showed a 100% reduction in tumor lesion size in a patient with urothelial carcinoma and an 81% reduction in target lesions in a patient with metastatic melanoma resistant to prior therapy [4] - The combination therapy is noted for its favorable safety profile and evidence of durable disease control [2][4] Future Directions - The company is exploring optimal combinations and indications for further clinical studies of NUC-3373 while maintaining a cash runway into 2029 [2]